ALDX
Aldeyra Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.50 / 10
Outperform
With a fund flow rating of 7.51/10, the stock shows robust fund flow characteristics. Supportive momentum from overall, block, and Extra-large trends is partially offset by concerning Small, Medium, and Large patterns, pointing to positive capital flow trajectory. The analyst community expresses overwhelmingly bullish analyst consensus with strong conviction. Ratings composition: Strong Buy(100.0%) representing 1 analyst views, supported by 5.49 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-10
InstitutionBTIG
Times predicted2
Historical Win Rate100.0%
What is the analyst consensus for ALDX?
- ALDX holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.50/10 (Outperform).
